An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin.

Trial Profile

An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Gastrointestinal cancer; Nelson's syndrome; Neuroendocrine tumours; Pancreatic cancer; Pituitary tumours
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 15 Jun 2016 Status changed from completed to discontinued.
    • 17 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 May 2014 Planned End Date changed from 1 Jan 2014 to 1 Apr 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top